Sutro Biopharma (STRO) Non-Current Debt (2018 - 2022)

Sutro Biopharma has disclosed Non-Current Debt across 5 years of filings, most recently posting $3.8 million for Q4 2022.

• Non-Current Debt for Q4 2022 came in at $3.8 million, down 76.04% year-over-year; the trailing twelve-month figure through Dec 2022 was $3.8 million (down 76.04% YoY), and the FY2022 annual result was $3.8 million, down 76.04% from the prior year.
• Non-Current Debt came in at $3.8 million for Q4 2022 at Sutro Biopharma, down from $6.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $24.7 million in Q1 2021 to a low of $3.8 million in Q4 2022.
• The 5-year median for Non-Current Debt is $12.1 million (2018), against an average of $14.6 million.
• Across the five-year window, Non-Current Debt soared 343.84% in 2020 and plunged 76.04% in 2022, its largest moves.
• Sutro Biopharma's Non-Current Debt stood at $10.0 million in 2018, then slipped by 11.24% to $8.9 million in 2019, then soared by 176.53% to $24.5 million in 2020, then tumbled by 35.88% to $15.7 million in 2021, then slumped by 76.04% to $3.8 million in 2022.
• The last three Non-Current Debt figures came in at $3.8 million (Q4 2022), $6.8 million (Q3 2022), and $9.8 million (Q2 2022), per Business Quant data.